Effectiveness of REGEN‐COV antibody cocktail against the B.1.617.2 (delta) variant of SARS‐CoV‐2: A cohort study

Kumar, Jagadeesh; Banu, Sofia; Sasikala, M.; Parsa, Kishore V. L.; Sowpati, Divya Tej; Yadav, Rupali; Tallapaka, Karthik Bharadwaj; Siva, Archana Bharadwaj; Vishnubhotla, Ravikanth; Rao, Guduru Venkat; Reddy, Duvvur Nageshwar

doi:10.1111/joim.13408

Cited by 16 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 477 The clinical efficacy of REGEN-COV was maintained even in the presence of the SARS-CoV-2 delta variant. 478 Different regulatory agencies approved REGEN-COV for treatment of people 12 years of age or older with mild to moderate COVID-19 who are at high risk for progression to severe disease and as prophylactic therapy for people exposed to SARS-CoV-2-infected individuals ( Table 2 ).…”

Section: Treatmentmentioning

confidence: 99%

Two Years into the COVID-19 Pandemic: Lessons Learned

et al. 2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan, China, causing a respiratory disease called coronavirus disease 2019 (COVID-19), which has massively impacted global public health and caused widespread disruption to daily life. The crisis caused by COVID-19 has mobilized scientists and public health authorities across the world to rapidly improve our knowledge about this devastating disease, shedding light on its management and control, and spawned the development of new countermeasures. Here we provide an overview of the state of the art of knowledge gained in the last 2 years about the virus and COVID-19, including its origin and natural reservoir hosts, viral etiology, epidemiology, modes of transmission, clinical manifestations, pathophysiology, diagnosis, treatment, prevention, emerging variants, and vaccines, highlighting important differences from previously known highly pathogenic coronaviruses. We also discuss selected key discoveries from each topic and underline the gaps of knowledge for future investigations.

show abstract

Section: Treatmentmentioning

confidence: 99%

Two Years into the COVID-19 Pandemic: Lessons Learned

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The B.1.617 variant contains both E484 and L452 mutations, which presumably alter viral antigenicity. A recent study showed that the B.1.617.1 variant was resistant to the mAb bamlanivimab, but it was not resistant to imdevimab or a cocktail of casirivimab and imdevimab [ 40 ]. In our study, we tested 16 mAbs; the effects of four were reduced by all B.1.617 sub-lineages, whereas the effects of two were abolished by either B.1.617.1 and B.1.617.3 or B.1.617.2 variants because of differences involving T478K and E484Q mutations.…”

Section: Resultsmentioning

confidence: 99%

“…However, the antibody-escaping capacity dose not equal to the increased breakthrough infection. Another reason may be the fast waning of vaccine or infection elicited neutralization antibodies, as well as the barrier IgA protection [ 40 ]. Therefore, a booster dose maybe quite helpful, as it could enhanced the neutralization antibody to a large extend.…”

Section: Resultsmentioning

confidence: 99%

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity

Zhang

et al. 2022

Emerging Microbes & Infections

View full text Add to dashboard Cite

SARS-CoV-2 has caused the COVID-19 pandemic. B.1.617 variants (including Kappa and Delta) have been transmitted rapidly in India. The transmissibility, pathogenicity, and neutralization characteristics of these variants have received considerable interest. In this study, 22 pseudotyped viruses were constructed for B.1.617 variants and their corresponding single amino acid mutations. B.1.617 variants did not exhibit significant enhanced infectivity in human cells, but mutations T478K and E484Q in the receptor binding domain led to enhanced infectivity in mouse ACE2-overexpressing cells. Furin activities were slightly increased against B.1.617 variants and cell–cell fusion after infection of B.1.617 variants were enhanced. Furthermore, B.1.617 variants escaped neutralization by several mAbs, mainly because of mutations L452R, T478K, and E484Q in the receptor binding domain. The neutralization activities of sera from convalescent patients, inactivated vaccine-immunized volunteers, adenovirus vaccine-immunized volunteers, and SARS-CoV-2 immunized animals against pseudotyped B.1.617 variants were reduced by approximately twofold, compared with the D614G variant.

show abstract

“…We illustrate this method using the example of Omicron Spike gene which contains 37 mutations (dispersed over nearly 3kb) as compared to the wild-type Spike gene. We followed a similar strategy to create the Delta Spike construct previously, which was successfully used in the pseudovirus neutralization assay reported by Kumar et al [3], validating this approach.…”

Section: Introductionmentioning

confidence: 97%

An efficient and cost-effective method for directed mutagenesis at multiple dispersed sites – a case study with Omicron Spike DNA

Rani

Parsa

Chatti

et al. 2022

Preprint

View full text Add to dashboard Cite

Site directed mutagenesis is an invaluable technique which enables the elucidation of the contribution of specific residues to protein structure and function. The simultaneous introduction of mutations at a large number of sites (>10), singly and in multiple combinations is often necessary to fully understand the functional contributions. We report a simple, efficient, time and cost effective method to achieve this using commonly available molecular biology reagents and protocols, as an alternative to gene synthesis. We demonstrate this method using the Omicron Spike DNA construct as an example, and create a construct bearing 37 mutations (as compared to wild-type Spike DNA), as well as four other constructs bearing subsets of the full spectrum of mutations. We believe that this method can be an excellent alternative to gene synthesis, especially when three or more variants are required.

show abstract

Effectiveness of REGEN‐COV antibody cocktail against the B.1.617.2 (delta) variant of SARS‐CoV‐2: A cohort study

Cited by 16 publications

References 10 publications

Two Years into the COVID-19 Pandemic: Lessons Learned

Two Years into the COVID-19 Pandemic: Lessons Learned

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity

An efficient and cost-effective method for directed mutagenesis at multiple dispersed sites – a case study with Omicron Spike DNA

Contact Info

Product

Resources

About